CDIO

Cardio Diagnostics Holdings, Inc.
CAPPED RATING

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Cardio Diagnostics Holdings, Inc. (CDIO) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-). The rating has held at C- for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
C
Factor Score 2.2 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
D-
Factor Score 1.1 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -7.4
EV / EBITDA 0.1
Rev Growth YoY -28.3%
Gross Margin N/M
Price Return 3M -13.9%
Price Return 12M -51.8%
Catalyst Signal 0.00
Market Cap $5.5M
TTM Revenue $14.4K
Price / Sales 380.9
ROE -75.4%

Historical Factor Score Progression

Held C- for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C (2.2) D (1.2) D- (1.1) C (2.5) C+ (2.6) C- (1.9)
2026-11-04 C (2.4) D- (1.1) D- (1.1) C+ (2.8) C+ (2.7) C- (2.0)
2026-10-28 C (2.4) D- (1.1) D- (1.1) C+ (2.8) C+ (2.7) C- (2.0)
2026-10-21 C (2.4) D- (1.1) D- (1.1) C+ (2.6) C+ (2.6) C- (2.0)
2026-10-14 C (2.4) D- (1.1) D- (1.1) C+ (2.7) C+ (2.6) C- (2.0)
Page 1 of 4